BIND Biosciences, Inc. Appoints Industry Veteran Daniel Lynch as Chairman of the Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, today announced the appointment of Daniel S. Lynch as Chairman of the company’s board of directors.